Inclusion Criteria:

          -  Adult patient, >/= 18 years of age

          -  Histologically confirmed, unresectable Stage IIIB or IV non-small cell lung cancer
             (NSCLC)

          -  No prior treatment for unresectable Stage IIIB or IV NSCLC

          -  Measurable radiographic evidence of disease according to RECIST v1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

        Exclusion Criteria:

          -  Prior exposure to agents targeting either the Hepatocyte Growth Factor (HGF) or MET
             pathway

          -  Exposure to an investigational or marketed agent that can act by EGFR inhibition

          -  Pleural effusion, pericardial fluid, or ascites requiring drainage every other week or
             more frequently

          -  Brain metastasis or spinal cord compression not definitively treated with surgery
             and/or radiation, or previously diagnosed and treated central nervous system (CNS)
             metastases or spinal cord compression without evidence of clinically stable disease
             for >/=4 days. Note: Patients with treated CNS metastases who are asymptomatic and on
             a stable dose of corticosteroids for >/= 14 days prior to randomization are eligible.

          -  History of another malignancy in the previous 5 years, unless cured by surgery alone
             and continuously disease-free

          -  Radiographically evident interstitial lung disease , concurrent infection, or a
             history of any of these conditions

          -  Inadequate hematologic, biochemical, and organ function

          -  Pregnant or lactating women

          -  Life expectancy of < 12 weeks

          -  Receipt of an investigational drug within 28 days prior to initiation of study
             treatment